Founded in 1998, the Swiss Biotech Association is a non-profit, member-driven organisation that represents the interests of the Swiss biotech industry. The association aims to create ideal framework conditions and to facilitate access to talent, new technologies and financial resources. Swissmedic is a member of the Swiss Biotech Association, to which it contributes its expertise as a regulatory authority. The Agency for Therapeutic Products ensures that both scientific and regulatory aspects are taken into account.
In this way, the Swiss biotech industry can continue to grow and consolidate Switzerland’s position as a key player at the forefront of bioscience innovation.
Swiss Biotech Day takes place on 24-25 April in Basel. It is one of the leading biotechnology conferences in Europe with ideal networking opportunities for over 1,100 participants from around the globe. The Swiss Biotech Report 2023 was presented at the event. The key figures for the past year are as follows:
- 47 new Swissmedic authorisations
- R&D investment set a new record at CHF 2.7 billion
- The cumulative sales of 354 biotech companies amounted to CHF 6.8 billion
- 19,000 employees work in the sector
With its commitment to the Swiss Biotech Association, Swissmedic is fulfilling the Federal Council’s requirements. The strategic objectives provide for, among other things, the Agency for Therapeutic Products’ actively supporting the development of innovative therapeutic products, thereby facilitating rapid access to innovative treatments for patients in Switzerland. Furthermore, the master plan “Federal measures for the promotion of biomedical research and technology 2022-2026” aims to ensure that the public has access to new medicinal products and treatments as quickly as possible.